The majority of T2D subjects were treated with oral hypoglycemic agents alone or in combination with insulin (90% metformin, 17% GLP-1 analogs, 17% SGLT2 inhibitors, 34% insulin therapy). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.